Evidence map›Paper›PMID 34154629›Full record

ArticleJournal of nanobiotechnology2021

Use of magnetic nanotrap particles in capturing Yersinia pestis virulence factors, nucleic acids and bacteria.

Alexandra N Ii, Shih-Chao Lin, Benjamin Lepene, Weidong Zhou, Kylene Kehn-Hall, Monique L van Hoek

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Multiplex PCR System for the Diagnosis of Plague.Current molecular medicine · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Alexandra N Ii *School of Systems Biology, George Mason University, Manassas, VA, 20110, USA.
Shih-Chao Lin *School of Systems Biology, George Mason University, Manassas, VA, 20110, USA.
Benjamin LepeneCeres Nanosciences, 9460 Innovation Drive, Manassas, VA, 20110, USA.
Weidong ZhouCenter for Applied Proteomics and Personalized Medicine, George Mason University, Manassas, VA, 20110, USA.
Kylene Kehn-HallSchool of Systems Biology, George Mason University, Manassas, VA, 20110, USA.
Monique L van HoekSchool of Systems Biology, George Mason University, Manassas, VA, 20110, USA. mvanhoek@gmu.edu.ORCID http://orcid.org/0000-0003-1679-4899
George Mason University · USCeres Nanosciences · USNational Taiwan Ocean University · TW

Funding

Defense Threat Reduction Agency HDTRA1-17-C-0069
6 · The paper itself

Abstract

backgroundMany pathogens, including Yersinia pestis, cannot be consistently and reliably cultured from blood. New approaches are needed to facilitate the detection of proteins, nucleic acid and microorganisms in whole blood samples to improve downstream assay performance. Detection of biomarkers in whole blood is difficult due to the presence of host proteins that obscure standard detection mechanisms. Nanotrap® particles are micron-sized hydrogel structures containing a dye molecule as the affinity bait and used to detect host biomarkers, viral nucleic acids and proteins as well as some bacterial markers. Nanotraps have been shown to bind and enrich a wide variety of biomarkers and viruses in clinically relevant matrices such as urine and plasma. Our objective was to characterize the binding ability of Nanotrap particle type CN3080 to Y. pestis bacteria, bacterial proteins and nucleic acids from whole human blood in order to potentially improve detection and diagnosis.

resultsCN3080 Nanotraps bind tightly to Yersinia bacteria, even after washing, and we were able to visualize the co-localized Nanotraps and bacteria by electron microscopy. These magnetic hydrogel Nanotraps were able to bind Yersinia DNA, supporting the utility of Nanotraps for enhancing nucleic acid-based detection methods. Nanotraps were capable of increasing Y. pestis nucleic acid yield by fourfold from whole human blood compared to standard nucleic acid extraction. Interestingly, we found CN3080 Nanotraps to have a high affinity for multiple components of the Yersinia type III secretion system (T3SS), including chaperone proteins, Yop effector proteins and virulence factor protein LcrV (V). Using Nanotraps as a rapid upstream sample-prep tool, we were able to detect LcrV in human blood by western blotting with minimal blood interference in contrast to direct western blotting of blood samples in which LcrV was obscured. We were able to computationally model the interaction of LcrV with the CN3080 Nanotrap dye and found that it had a low delta-G, suggesting high affinity. Importantly, Nanotraps were also able to enhance detection of secreted Yersinia proteins by mass spectrometry.

conclusionUpstream use of magnetic CN3080 Nanotrap particles may improve the downstream workflow though binding and enrichment of biomarkers and speed of processing. Utilization of Nanotrap particles can improve detection of Yersinia pestis proteins and nucleic acid from whole human blood and contribute to downstream assays and diagnostics including molecular methods such as sequencing and PCR and protein-based methods.

Indexed as

MagneticsBacteriaBacterial ProteinsBiomarkersBloodBlotting, WesternDNA, BacterialHumansHydrogelsMagnetic PhenomenaMolecular Docking SimulationNanotechnologyNucleic AcidsProteomicsRNA, Ribosomal, 16SVirulence FactorsBacterial ProteinsBiomarkersDNA, BacterialHydrogelsNucleic AcidsRNA, Ribosomal, 16SVirulence FactorsDNAF1 antigenLcrVNucleic acidPlagueProteinProteomicsSample preparationT3SSYersinia pestis

Identifiers

PMID34154629
PMCPMC8215484
OpenAlexW3177185143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.